Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Smoldering Myeloma Risk of Infections
Smoldering Myeloma Risk of Infections
Smoldering Myeloma risk of infections. According to the study linked below, SMM patients are at increased risk of infections. In this day of influenza, covid, etc. it seems to me that preventing infections is an important issue.
I have posted the video below of Dr. Urvi Shah talking about how a high fiber diet can
- Slow or prevent SMM from becoming full MM and
- Enhance the immune system of SMM patients.
At the 2:00 minute mark, listen for Dr. Shah to talk about diet, reduced inflammation markers as well as enhanced immune function due to diet.
The potential of non-drug interventions in SMM and MGUS: diet and lifestyle
While Dr. Shah’s trial does not explore other non-conventional therapies to reduce the risk of SMM becoming MM, other studies indicate that there are other lifestyle therapies that can reduce the risk of SMM becoming full MM.
- Nutritional supplements
- Whole body hyperthermia
- Exercise
- Sleep
Others have shown the ability to reduce the risk of MM.
I am a long-term MM survivor. I rely on supplementation, diet, and lifestyle therapies to help me remain MM-free.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about managing MGUS, SMM and MM with both conventional and non-conventional therapies.
Thanks,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Immunoparesis is the suppression or weakness of a patient’s uninvolved immunoglobulins, the healthy antibodies that help fight infections. It is a frequent finding in multiple myeloma (MM) patients and other conditions like MGUS, where the abnormal plasma cells crowd out the healthy plasma cells needed to produce these protective immunoglobulins. This makes patients with immunoparesis more vulnerable to infections because their immune system is compromised.
Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
Abstract
Infections are a major cause of morbidity and mortality in multiple myeloma (MM). While increased infection risk has been shown in monoclonal gammopathy of undetermined significance (MGUS), data are limited for smoldering multiple myeloma (SMM).
We used data from the iStopMM study, which screened 75,422 Icelandic individuals aged ≥40 years for MM precursors. Individuals diagnosed with SMM were matched by age and sex with MGUS-free comparators (1:5 ratio) and with individuals with MGUS (1:1 ratio).
Infection outcomes were derived from nationwide registries of ICD-10 diagnostic codes and antimicrobial prescriptions. Cox proportional hazards models estimated infection risk, adjusted for immunoparesis. 188 SMM individuals were matched to 188 MGUS individuals and 162 SMM individuals were matched to 810 comparators.
Individuals with SMM had significantly more infections (HR 1.36, 95% CI 1.07–1.73) and antibacterial prescriptions (HR 1.24, 95% CI 1.01–1.52) than the comparators. Compared to MGUS, individuals with SMM also had more infections (HR 1.37, 95% CI 1.00–1.87).
Adjusting for immunoparesis attenuated the associations, suggesting it may partially mediate infection risk. This first screened cohort of SMM shows a significantly increased infection risk, compared to both MGUS and to individuals without MM precursors, suggesting an underrecognized infection burden in SMM…
To summarize, in our population-based screened SMM cohort, we found that individuals with SMM have a significantly increased risk of infections compared to both individuals with MGUS and individuals without MGUS, a risk that was only partly explained by immunoparesis.
Additionally, individuals with SMM received significantly more antibacterial prescriptions, suggesting a potentially larger bacterial infectious burden. These findings reveal an underrecognized vulnerability in SMM, even in a low-risk cohort.
A better understanding of the underlying mechanisms may help identify patients who could benefit from preventive measures, enhanced surveillance, or early therapeutic intervention.
Smoldering Myeloma risk of infections Smoldering Myeloma risk of infections